Vibegron: Effect, Application & Important Notes
Vibegron is a selective beta-3 adrenoceptor agonist approved for the treatment of overactive bladder (OAB). Unlike older anticholinergic agents, vibegron acts directly on the beta-3 receptors of the bladder smooth muscle, relaxing the detrusor muscle without significant anticholinergic side effects.
Since its approval in the United States in 2020 and subsequent European market authorization, vibegron has established itself as a well-tolerated alternative for patients who cannot tolerate or respond insufficiently to antimuscarinic drugs. The once-daily oral administration simplifies long-term management of this chronic condition.
Mechanism of Action
Vibegron selectively activates beta-3 adrenoceptors located on the smooth muscle cells of the urinary bladder. Stimulation of these receptors activates adenylate cyclase, increasing intracellular cAMP levels. This leads to relaxation of the detrusor muscle, increasing bladder capacity and reducing involuntary contractions. Because vibegron has minimal affinity for beta-1 and beta-2 receptors, cardiovascular and pulmonary side effects are uncommon. The receptor selectivity also explains the absence of the cognitive impairment and constipation associated with anticholinergic drugs.
Indications
Vibegron is indicated for adults with overactive bladder syndrome with symptoms of urge urinary incontinence, urgency, and urinary frequency. OAB affects an estimated 10 to 17 percent of the adult population and significantly impairs quality of life. Vibegron is suitable for patients who have not responded adequately to behavioral interventions or who need pharmacological support as adjunct therapy. It is not indicated for stress incontinence or urinary tract infections.
Dosage and Administration
The recommended dose is 75 mg once daily, taken orally with or without food. Tablets should be swallowed whole and can be crushed for patients who have difficulty swallowing. No dose adjustment is required for mild to moderate renal impairment; vibegron is not recommended in severe renal impairment (eGFR below 15 mL/min). In mild to moderate hepatic impairment, dose adjustment is generally not necessary. The manufacturer recommends medical supervision for patients with severe hepatic impairment.
Side Effects
The most frequently reported adverse effects in clinical trials include headache (occurring in about 4 percent of patients), nasopharyngitis, urinary tract infection, and nausea. Unlike antimuscarinics, vibegron does not cause significant dry mouth or constipation. Urinary retention has been reported rarely and is relevant primarily in patients with bladder outlet obstruction. Blood pressure elevation has been observed in some patients, warranting monitoring in hypertensive individuals. Overall, vibegron demonstrates a favorable safety profile compared to older OAB treatments.
Interactions
Vibegron is a substrate of P-glycoprotein (P-gp) and is metabolized partly by CYP3A4. Co-administration with strong P-gp inhibitors such as cyclosporine may increase vibegron plasma concentrations. Digoxin plasma levels may increase when co-administered with vibegron; monitoring of digoxin levels is recommended. Vibegron does not have clinically relevant interactions with most common antihypertensives or anticoagulants, but a comprehensive medication review is advisable before initiation.
Special Notes
Vibegron is a prescription-only medicine. Patients with known bladder outlet obstruction, such as benign prostatic hyperplasia, should use vibegron with caution due to the risk of urinary retention. The drug is not recommended during pregnancy or breastfeeding due to insufficient data. Patients should inform their physician of all concurrent medications to identify potential interactions. Regular follow-up visits are recommended to assess treatment response and tolerability.
Related Topics
Frequently Asked Questions
How quickly does vibegron take effect?
Many patients notice improvement in urgency and frequency within the first two weeks. The full therapeutic effect typically develops over four to eight weeks of regular use.
Can vibegron be taken long-term?
Clinical studies have demonstrated tolerability over 52 weeks. Long-term use requires regular medical review to assess ongoing benefit and monitor for adverse effects.
What distinguishes vibegron from older bladder medications?
Vibegron acts via beta-3 receptors rather than blocking muscarinic receptors, which means it avoids the typical anticholinergic side effects such as dry mouth, constipation, and cognitive impairment that are common with older agents like oxybutynin.
Sources
- EMA: Vibegron Summary of Product Characteristics 2023
- Staskin D et al: Vibegron for Overactive Bladder. N Engl J Med 2020
- ICS Guidelines on Overactive Bladder 2023